Clinical trial
T900607 in Treating Patients With Unresectable Liver Cancer
NCT00054262 · University Hospitals Seidman Cancer Center, Other · Completed
Key facts
| NCT number | NCT00054262 |
|---|---|
| Title | T900607 in Treating Patients With Unresectable Liver Cancer |
| Official title | A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma |
| Lead sponsor | University Hospitals Seidman Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | T900607 |
| Start date | Nov 1, 2002 |
| Primary completion | Mar 1, 2004 |
| Completion | Sep 1, 2010 |
| First posted | Feb 6, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: